Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23319807 | 0.85 | GABRA1 (0.37) | GABRA1GABRB1TRPA1LMNACHRM1 | |
| SCHEMBL723605 | 0.77 | — | — | |
| SCHEMBL12896003 | 0.76 | ADRA2A (0.35) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| Hydrochloric Acid SCHEMBL18189392 | 0.75 | UHRF1 (0.35) | — | |
| SCHEMBL24850162 | 0.74 | TRPA1 (0.31) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL19590671 | 0.73 | POLB (0.33) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL11947091 | 0.73 | RPS6KA3 (0.32) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL20285947 | 0.73 | LMNA (0.36) | GABRA1GABRB1TRPA1LMNACHRM1 | |
| SCHEMBL26780057 | 0.73 | GABRA1 (0.39) | GABRA1GABRB1TRPA1LMNACHRM1 | |
| SCHEMBL25927959 | 0.73 | GABRA1 (0.32) | GABRA1GABRB1TRPA1LMNACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2019059161-A1 | PYRIDONE COMPOUND AND AGRICULTURAL AND HORTICULTURAL GERMICIDE HAVING SAME AS ACTIVE INGREDIENT | 三井化学アグロ株式会社 | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | GABRA1 4210/4885GABRB1 4052/4885TRPA1 3983/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | GABRA1 3751/4885GABRB1 3677/4885TRPA1 2972/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | GABRA1 3751/4885GABRB1 3677/4885TRPA1 2972/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | GABRA1 3463/4885GABRB1 3471/4885TRPA1 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.